Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Oct 11, 2007

Title: Methods for Directing DNA Methylation in Mammalian Cells Using Homologous, Short Double-Stranded RNAs
Number: 20070231907
Filed: May 29, 2007
Lead Inventor: John Rossi, City of Hope
“The invention provides methods for methylating a gene of interest in a cell,” the patent application’s abstract states. “The methods include exposing a mammalian cell to an siRNA molecule which is specific for a gene of interest in the cell. The methods also include introducing into the cell DNA sequences encoding a sense strand and an antisense strand of an siRNA which is specific for the gene of interest. The siRNA directs methylation of the gene of interest.”

Title: C-Met siRNA Adenovirus Vectors Inhibit Cancer Cell Growth, Invasion, and Tumorigenicity
Number: 20070232555
Filed: March 28, 2005 PCT Filed: March 28, 2005
Lead Inventor: Nariyoshi Shinomiya, Van Andel Research Institute
“Suppression of the hepatocyte growth factor/scatter factor-Met signaling pathway by targeting the Met protein tyrosine kinase was tested as strategy for suppressing tumor growth,” the patent application’s abstract states. “Using RNA interference technology and adenoviruses carrying siRNA target sequences … Met expression in mouse, dog, and human tumor cells [was] ... dramatically reduced.”
The abstract adds that “Met was suppressed using Ad Met siRNA in mouse mammary tumor cells and Met-transformed cells, as well as human prostate cancer, sarcoma, glioblastoma, gastric, and ovarian cancer cells. Furthermore, the Ad Met siRNA infection reversed transformed cell morphology. Ad Met siRNA killed cancer cells by inducing apoptosis. RNAi targeting Met suppressed HGF/SF-mediated scattering as well as ligand-mediated invasion activity and growth of tumor cells,” it notes. “Met siRNA infection also abrogated downstream Met signaling to molecules such as Akt and p44/42 MAPK. Importantly, the Met siRNA triggered apoptosis was correlated to suppressed tumorigenicity in vivo. Intro-tumoral infection with c-met siRNA adenovirus vectors produced significant reduction in tumor growth.”

Title: siRNA Targeting Cell Division Cycle-Like 5
Number: 20070232797
Filed: April 9, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CDC2L5.”          

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.